CNMAU-8 is under clinical development by Clene and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase III drugs for Amyotrophic Lateral Sclerosis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how CNMAU-8’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CNMAU-8 is under development for the treatment of relapsing multiple sclerosis, chronic optic neuropathy associated with relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis or non-active secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, neuronal aging-related deficits and Alzheimer’s disease. The drug candidate nanocrystalline gold suspension formulated as a nanosuspension. It is administered through oral route. It is a small molecule developed based on Clean-Surface Nanosuspension (CSN) technology. It was also under development for amyotrophic lateral sclerosis.
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. It is headquartered in Salt Lake City, Utah, the US.
For a complete picture of CNMAU-8’s drug-specific PTSR and LoA scores, buy the report here.